Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2014. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMR) under the GlaxoSmithKline 2009 Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity plan transactions.
- Share Price (Ordinary Shares): 1,572.00 pence
- Share Price (ADS): $54.40
- Transaction Type: Notional re-investment of dividends paid on July 10, 2014.
Material Changes
The filing details increases in notional interests for specific Directors and PDMRs following the dividend re-investment. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of internal equity plan activity.
Investor Verification Points
- Verify the specific number of Ordinary Shares and ADSs allocated to each Director and PDMR listed in the table.
- Confirm the vesting conditions and measurement periods applicable to the GlaxoSmithKline 2009 Performance Share Plan.
- Review the dividend payment date of July 10, 2014, to understand the basis for the notional re-investment.